Skip to main content
Oncogenesis logoLink to Oncogenesis
. 2019 Sep 11;8(9):51. doi: 10.1038/s41389-019-0160-0

Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication

Y Ishikawa 1,#, K Nakayama 1,#, M Morimoto 1, A Mizutani 1, A Nakayama 1, K Toyoshima 1, A Hayashi 1, S Takagi 1, R Dairiki 1, H Miyashita 1, S Matsumoto 2, K Gamo 1, T Nomura 1, K Nakamura 1,
PMCID: PMC6739332  PMID: 31511500

Correction to: Oncogenesis

10.1038/oncsis.2017.76 Published online 11 September 2017

The FAB classification of OCI-M2, GF-D8, CMK-11-5, and THP-1 cell lines in Table 1 was wrong. This error has been fixed in the revised table.

Table 1.

Synergy score of T-3775440/pevonedistat combination in an AML cell panel

graphic file with name 41389_2019_160_Tab1_HTML.jpg

NOTE: Combination index (CI) values in the range 0–0.7 and 0.7–1.3 are classified as synergy and additivity, respectively. When CI values were not associated, nonlinear blending values greater than 20 and between −20 and +20 were classified as synergy and additivity, respectively. Heat maps are color-coded based on the combination effects: Green, synergy; orange, additive; red, subadditive.

Footnotes

The original article can be found online at 10.1038/oncsis.2017.76.

These authors contributed equally: Y. Ishikawa, K. Nakayama


Articles from Oncogenesis are provided here courtesy of Nature Publishing Group

RESOURCES